



COMMUNITY PARTNERSHIP AGREEMENT REVENUE SHARE

Frontiers Media SA, Avenue du Tribunal-Fédéral 34, 1005 Lausanne, Switzerland (**Frontiers**)

and

The Hellenic Society for Basic and Clinical Pharmacology, M. Asias 75, Athens 11527, Greece (**Organisation**)

Frontiers publishes the “Frontiers in” series of journals, including the journal Frontiers in Pharmacology, ISSN 1663-9812 (**Journal**).

The Organisation is engaged in promoting research and education in both basic and clinical pharmacology. It fosters advancements in molecular pharmacology and translational research, often organizing biennial scientific conferences to bridge findings between academia, research institutes, and clinical practices.

The parties wish to enter into a community partnership to support the Journal and its open-access distribution to the widest possible audience.

1. RESEARCH TOPICS

- 1.1. Organisation Participation.** The Organisation will participate in the Journal by proposing original research topics for collections of articles (**Organisation Research Topics**). Such Organisation Research Topics must not overlap with the same or substantially similar research topics in the Journal or already proposed to Frontiers. The Organisation will aim to contribute a minimum of 2 Organisation Research Topic posted in the Journal during each calendar year.
- 1.2. Recognition.** Frontiers will acknowledge the Organisation by including on their Research Topic landing pages:
 - a) an acknowledgement of initiation by the Organisation; and
 - b) a direct link to the Organisation’s website.
- 1.3. Frontiers Discretion.** Frontiers retains exclusive discretion on whether to post a Research Topic proposed by the Organisation and may reject it and any content submitted to it at any point.



2. REVENUE SHARE AND WAIVERS

- 2.1. **Revenue Share.** Frontiers will pay to the Organisation a fee equal to 15% of any article processing charges (**APCs**) actually received by Frontiers for articles published in an Organisation Research Topic (**Revenue Share**).
- 2.2. **Waivers.** Frontiers will grant the Organisation one complete APC waiver for each Organisation Research Topic posted in the Journal that contains at least 4 published non-editorial articles.
- 2.3. **Use of Waivers.** Waivers may be applied towards any articles published in the Journal by Organisation members.
- 2.4. **Waiver Expiry.** Waivers expire 12 months from the date they are awarded, after which they will automatically and immediately expire without value.
- 2.5. **Annual Statement.** Every January, Frontiers will provide the Organisation with a statement setting out the Revenue Share and waiver entitlement of the Organisation for the previous calendar year.
- 2.6. **Allocation.** Frontiers will provide any applicable Revenue Share and waivers to the Organisation within 30 calendar days of the annual statement.

3. ANNUAL CONFERENCE

- 3.1. **Attendance.** The Organisation will grant Frontiers a minimum of one free attendance pass at the Organisation's biannual conferences: "Panhellenic Congress of the Hellenic Society for Basic and Clinical Pharmacology".
- 3.2. **E-Book of Abstracts.** Subject to a minimum of articles be published in the Organisation Research Topic, as set by Frontiers, Frontiers will produce one free-of-charge e-book per conference, containing up to 300 abstracts from the Organiser's annual conference. If the e-book exceeds 300 abstracts, Frontiers' standard rates will apply. The Organiser agrees to provide Frontiers with the conference abstracts without undue delay following the conference.

4. COMMUNICATIONS

- 4.1. **Joint Announcement.** In collaboration with the Organisation, Frontiers will draft a joint announcement on this partnership which both parties will post on their respective social media accounts.
- 4.2. **Organisation Communications.** The Organisation will:
 - a) include a statement that the Organisation endorses the Journal as a recommended publishing outlet on its website and in its newsletters;
 - b) display the Frontiers name and logo on its website landing page and at related conferences;



- c) display a prominent direct web link to the Journal from its website landing page; and
- d) communicate Journal-related information to its members on a regular basis in its newsletter where the Organisation deems the content relevant.

4.3. Frontiers Communications. Frontiers will:

- a) include a statement that the Organisation endorses the Journal on the “About” page of the Journal;
- b) display the Organisation’s name and logo on the “About” page of the Journal; and
- c) promote the Organisation via applicable Frontiers social media streams and the Frontiers official blog where Frontiers deems the content relevant and consistent with Frontiers Rules.

4.4. Mutual Protection. Neither party will do or refrain from doing something that is likely to detrimentally affect the other party’s reputation and neither will suggest the other party is behind an initiative without the other party’s prior written consent.

4.5. Trade Names and Marks. For the avoidance of doubt, as between the parties, all intellectual property rights in the Organisation’s name and registered trademarks will remain the exclusive property of the Organisation, and all intellectual property rights in the Frontiers name and registered trademarks and/or the Journal name and related registered trademarks will remain the exclusive property of Frontiers.

5. PUBLISHING STANDARDS

5.1. Frontiers Rules. All and any applicable Frontiers rules, procedures, ethical guidelines, editorial policies and/ or conditions, as updated from time to time (Frontiers Rules), apply to the Journal and any Organisation Research Topic.

5.2. Compliance. In supporting Organisation Research Topics or submitting any manuscripts for publication, the Organisation will comply with applicable Frontiers Rules and nothing in this agreement requires, or can be interpreted as requiring, either party to apply anything but the highest standards of scientific and editorial integrity and practices.

5.3. Non-compliance. If the Organisation becomes aware of any non-compliance or suspected non-compliance with Frontiers Rules including any fraud, defamation or other offensive material related to the Journal:

- a) the Organisation will promptly inform Frontiers and provide assistance as may be reasonably requested by Frontiers; and
- b) Frontiers will use its best endeavours to resolve the issue which may include removing, retracting, correcting or redacting improper material.

6. DATA PROTECTION

6.1. Data Protection Laws. Data Protection Laws mean all data protection and privacy laws, regulations and mandatory guidance that may be applicable to the parties, including:



- a) the Swiss Federal Act on Data Protection of 19 June 1992, any subsequent version thereof (including the revised Federal Act on Data Protection of 25 September 2020 which entered into force on 1 September 2023) and its ordinances (**FADP**);
- b) Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC and its amendments (**GDPR**);
- c) the GDPR as amended and incorporated into UK law under the UK European Union (Withdrawal) Act 2018, and applicable secondary legislation (**UK GDPR**);
- d) and any related national laws or regulations.

6.2. Independent Data Controller. When processing personal data in connection with this agreement, each party will act as an independent data controller (as defined in data protection laws) and will be responsible to ensure that its processing of personal data in connection with this agreement complies with Data Protection Laws.

6.3. Processing. Where the performance of this agreement requires that the parties process personal data, for instance by sharing personal data between them, each will:

- a) ensure that it has a lawful basis for processing personal data, having informed all relevant data subjects about this sharing of personal data with the other party as required by Data Protection Laws;
- b) ensure that personal data is processed only to the extent necessary for the performance of this agreement;
- c) implement appropriate technical and organisational measures to ensure the security of the personal data;
- d) take any measures necessary to ensure that personal data is adequately protected in case of transfer to a recipient located outside the European Union/EEA, the United Kingdom or Switzerland;
- e) ensure any third-party service providers engaged in connection with this agreement are subject to appropriate data protection obligations;
- f) notify the other party without undue delay in the event of personal data breach, and
- g) cooperate with the other party in responding to any requests from data subjects exercising their rights under Data Protection Laws.

6.4. Deletion. Where a party receives personal data from the other party in connection with this agreement, the receiving party will delete or return such personal data to the disclosing party promptly after termination of the agreement, unless the receiving party has a legal basis to keep processing such personal data for a longer period.



- 6.5. Data Processing Addendum.** The parties agree to complete this agreement, including by entering any additional data processing addendum or similar provisions, where necessary to comply with Data Protection Laws.

7. TERM AND TERMINATION

- 7.1. Term.** This agreement takes effect on the last date of signature and will have an initial term ending on 31 December 2027 (Expiry Date), unless terminated earlier in accordance with this agreement.
- 7.2. Renewal.** This agreement will renew for successive periods of 12 months on the Expiry Date or any anniversary thereof, unless terminated by a party with at least one months' written notice to the other before the end of the then-current contract period.
- 7.3. Early Termination.** Either party may terminate this agreement with immediate effect if the other party does or refrains from doing something that detrimentally affects the terminating party's reputation or otherwise materially breaches this agreement. The termination right is without prejudice to the terminating party's right to claim damages or request redress before any competent jurisdiction.

8. MISCELLANEOUS

- 8.1. Confidential Information.** Each party will keep non-public information of the other party confidential and will only use it as strictly necessary for this agreement.
- 8.2. Notices.** Notices by email must be to the parties' representative emails and are deemed given on the calendar day after sending.
- 8.3. Amendment.** This agreement will only be varied by written amendment signed by both parties.
- 8.4. No Partnership.** This agreement is not intended to and does not constitute a partnership, joint venture or agency relationship between the parties.
- 8.5. No Assignment.** The rights under this agreement are not transferable or assignable.
- 8.6. Entire Agreement.** This agreement constitutes the entire agreement and supersedes any prior oral or written understanding between the parties regarding this collaboration.

9. GOVERNING LAW AND JURISDICTION

- 9.1. Governing Law.** This agreement will be governed by the laws of Switzerland, excluding its conflict of laws principles.
- 9.2. Jurisdiction.** Any dispute arising out of or in connection with this agreement will be subject to the jurisdiction of the courts of Lausanne, Switzerland.



Frontiers Media SA

DocuSigned by:

51794EB39474428...

Giovanni Lippi
Chief Financial Officer
Date: 2026/04/13 | 12:26 CEST

DocuSigned by:

4AF47D01EDFD455...

Mehmet Toral
Chief Corporate Officer & General Counsel
Date: 2026/04/13 | 10:42 CEST

The Hellenic Society of Basic and Clinical Pharmacology

DocuSigned by:

89B0C958BB0F43C...

Evangelia Papadimitriou
HSBCP, President
Date: 2026/04/14 | 16:54 CEST

Signed by:

FBE23BAFDD7C4D5...

Antonios Goulas
HSBCP, Vice President
Date: 2026/04/19 | 11:08 CEST